

04/11/2025 Santiago de Cali, Colombia

**Hospital Universitario del Valle Evaristo García**

Dear WHO Expert Committee Members,


I write this letter on behalf of Hospital Universitario del Valle Evaristo García in support of inclusion of blinatumomab in the WHO Essential Medicines List.

As a pediatric oncologist, I have seen firsthand the impact of B-cell acute lymphoblastic leukemia in children — particularly in settings where access to innovative therapies is limited. Blinatumomab offers a highly effective, targeted option for these patients and has transformed outcomes in high-income countries.

Inclusion of blinatumomab in the WHO Model List of Essential Medicines for Children is a critical step toward expanding equitable access to this life-saving therapy in low- and middle-income countries. It would also support integration into national treatment protocols and facilitate procurement mechanisms aligned with WHO's Global Initiative for Childhood Cancer and addition to the Global Platform for Access to Childhood Cancer Medicines.

On behalf of my hospital and department, I strongly support this application and urge the Committee to approve blinatumomab for inclusion.

Sincerely,

A handwritten signature in black ink that reads "Jorge Luis Ramírez M". The signature is written in a cursive, flowing style.

Jorge Luis Ramírez Melo  
CC 1088730978  
e-mail georgerluis117@hotmail.com

Department of Hematology/Oncology  
Hospital Universitario del Valle Evaristo García, Cali, Colombia